NEW

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash, corresponding to an enterprise value of...

Medline Expands Catheter Portfolio

Medline and Consure Medical have announced a new agreement for Medline to exclusively distribute the QiVi MEC male external urine management device to help guard against catheter-associated urinary tract infections (CAUTI) and incontinence-associated dermatitis (IAD)....

FDA Clears Single-use Flexible Ureteroscope

Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later...

Brainlab, Fujifilm Offer Advanced Neurosurgery Capabilities

FUJIFILM Healthcare Americas Corporation and Brainlab recently announced that Brainlab will be the exclusive U.S. distributor of ARIETTA Precision Ultrasound for neurosurgery applications to be utilized with Brainlab’s surgical navigation systems. ARIETTA Precision,...

Caresyntax Hires Chief Strategy Officer, Joins AdvaMed

Caresyntax

Caresyntax, an enterprise-level digital surgery platform, has hired Rhonda Wallen as chief strategy officer and executive vice president of technology & evidence solutions to lead Caresyntax’s business development with medical device companies and develop new lines of business for other growing customer segments. Caresyntax also announced that it has joined AdvaMed.

“Actionable insights from the operating room play an essential role in helping medical device companies optimize and improve their products,” said Dennis Kogan, Caresyntax founder and CEO. “With Rhonda driving our medtech efforts, Caresyntax is uniquely positioned to provide companies with the real-world evidence necessary to not only improve their products, but ultimately to deliver the best possible surgical outcomes and demonstrate value for health care providers and payors.”

Wallen brings over 25 years of diverse experience in the medical technology and health care industries. She previously served as the senior vice president of marketing & corporate development at the SteriLumen division of Applied UV, which develops and acquires technologies for infection prevention and control.

At Caresyntax, Wallen will oversee growth of the company’s medical device and new business areas, including development and commercialization of clinical data-driven artificial intelligence and real-world evidence, as well as partnering and corporate development activities to support these efforts. She will also lead Caresyntax’s work with AdvaMed and its more than 400 members committed to advancing the medical device industry in order to achieve healthier lives around the world.

“Caresyntax has proven to be a trusted partner for over 1,000 hospitals, and I look forward to building on this solid foundation to bring the value of the Caresyntax platform to medical device companies,” Wallen said. “Medtech companies face increasing pressure to demonstrate their impact on lowering cost of care and improving patient outcomes. It is exciting to enable these companies’ continuous improvement with digital innovations, guided by real-world data.”

AdvaMed, the Advanced Medical Technology Association, advocates globally to bring patients access to life-saving medical technologies that meet the highest safety standards. AdvaMed’s Center for Digital Health promotes the critical role of data and digital medical technologies in improving patient care and advocates for public policies that advance digital health and the contributions of the medical technology industry to data-driven health care.

“Everything we do at Caresyntax is about making surgery smarter and safer,” Kogan said. “We’re proud to be part of an organization that supports our vision and shares our commitment.”

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X